Navigation Links
Selexis SA to Present and Partner at the BIO-Europe Spring
Date:3/8/2013

Geneva, Switzerland (PRWEB) March 08, 2013

Geneva, Switzerland (PRWEB) March 8, 2013 – Selexis SA announced today the Company’s vice president of business development, Armelle Gaussin, Ph.D., will present, “Proprietary and Unique Expression System for Versatile and Ubiquitous Transgene Expression” as part of the Cell Therapy/Regenerative Medicine Track on Tuesday, March 12, 2013 at 3:30 PM at the BIO-Europe Spring 2013 Partnering Conference being held March 11 – 13, 2013 at the Centre Covencions Internacional Barcelona (CCIB), in Barcelona, Spain. The Company will be also taking part in the pre-scheduled partnering meetings.

Presentation Abstract:
Selexis has developed a full expression platform based on proprietary epigenetic regulator elements, the Selexis Genetic Elements, enabling versatile and ubiquitous transgene expression in mammalian cells. This expression system has a wide range of application areas. In the cell therapy field, high and stable transgene expression is obtained in adult stem cells and also sustained upon cell differentiation both in vitro and in vivo. The platform also provides a simple, fast and reliable approach towards stable cell line development for the production of therapeutic proteins and offers a dedicated approach for difficult to express proteins.

Companies or individuals attending BIO-Europe Spring can schedule meetings with Selexis (registration required) by visiting: http://www.ebdgroup.com/bes/index.php

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins.

Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/BIO_Cell_therapy/regenerative_medicine/prweb10510565.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Merck scientist Daria Hazuda presents Bernard Fields Lecture at 20th Conference on Retroviruses and Opportunistic Infections (CROI)
3. Brad Paisley Partners with LiveBeyond for the "Beat This Summer Tour Presented by Cracker Barrel"
4. Celiac Disease Foundation to Present the Nation's Largest National Education Conference and Gluten-Free EXPO
5. United Representatives Invited to Sierra Leone
6. Greater representation of elderly patients in Phase III trials are needed
7. Independent panel to present findings on diagnosing gestational diabetes mellitus
8. Dr. Steve Carstensen Presents First Webinar for Dental Division of American Sleep and Breathing Academy
9. Einstein researchers present on imaging advances
10. Additional noteworthy research to be presented at the 2013 Genitourinary Cancers Symposium
11. S.T.A.R. Clinic Presents Becoming a Galactic Citizen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... ... provide first-quality education and high-level training standards to an international multidisciplinary group of ... disorder problems. As a way to further its mission at the grassroots level, ...
(Date:1/15/2017)... NY (PRWEB) , ... January 15, 2017 , ... In ... accounts in the United States for the asthma & allergy friendly mark. This certification ... to independently test and identify consumer products to be more suitable for the 60+ ...
(Date:1/15/2017)... CA (PRWEB) , ... January 15, 2017 , ... ... their choice of best physicians in eight Bay Area counties for 2017. Almost ... the healthcare research company managing the award process. Results were announced the magazine’s ...
(Date:1/14/2017)... CA (PRWEB) , ... January 13, 2017 , ... ... on Body and Soul, incorporating a magnesium-rich Mediterranean diet may lower the risk ... Café and Lounge notes that the many health and wellness benefits linked to ...
(Date:1/13/2017)... ... 2017 , ... A January 10 article in the Daily Star ... publication, with an emphasis on some new techniques that the publication says are becoming ... more casually to his patients and colleagues as Dr. J, comments that the best ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , January 16, 2017 According to a new ... Opportunity Analysis and Industry Forecast, 2014 - 2022," the global antioxidants market generated ... registering a CAGR of 6.42% during the forecast period. In the natural antioxidants ... volume in 2015. Continue Reading ... ...
(Date:1/16/2017)... , Jan. 16, 2017  Today, Analytics 4 Life ... devices, announced its expansion into JLABS @ ... life science incubators. As a resident in the space, ... medical device development and commercialization expertise. JLABS ... science innovation center that provides a flexible environment for ...
(Date:1/15/2017)... Le conseil d,administration de SurgaColl Technologies Ltd., le développeur ... de tissus humains, annonce la nomination de William (Bill) ... ... est un dirigeant expérimenté à l,international dans l,industrie des dispositifs ... de direction au sein de sociétés internationales spécialisées dans les ...
Breaking Medicine Technology: